Skip to content

Ginkgo Bioworks

US · DNA #3438 by market cap
11.47 -0.94 -7.57%
Live - 5344 symbols - heartbeat 286s ago · 2026-10-08 09:20
Pre-market 10.92 -4.80%
After-hours 11.31 -1.40%
Overnight 11.46 -0.09%
Market cap
772.39M
P/B
1.84
EPS
-5.64
Reader sentiment Are you bullish or bearish on DNA?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    TD Cowen Maintains Ginkgo Bioworks(DNA.US) With Buy Rating, Maintains Target Price $12
    Market Newswire · 2026/5/8
  • Company notice
    Sonim Technologies | 3: Initial statement of beneficial ownership of securities-10% Owner DNA Holdings Venture Inc.
    SEC · 2026/2/21
  • Rating change
    TD Cowen Maintains Ginkgo Bioworks(DNA.US) With Buy Rating, Cuts Target Price to $12
    Market Newswire · 2026/1/8
  • Company notice
    DNA Chip Research: Change report (special case target stocks, etc.)
    EDINET · 2025/6/6
  • TD Cowen Downgrades Ginkgo Bioworks(DNA.US) to Hold Rating, Cuts Target Price to $9
    Market Newswire · 2026/8/7
  • Company notice
    DNA Chip Research: Interim report.
    EDINET · 2025/6/3
  • Company notice
    DNA X | 8-K: DNA X, Inc. Reports First Quarter 2026 Financial Results
    SEC · 2026/5/21
  • Rating change
    BTIG Maintains Ginkgo Bioworks(DNA.US) With Sell Rating, Cuts Target Price to $5
    Market Newswire · 2026/3/12
  • Rating change
    William Blair Maintains Ginkgo Bioworks(DNA.US) With Sell Rating
    Market Newswire · 2026/8/14
  • BTIG Maintains Ginkgo Bioworks(DNA.US) With Sell Rating, Maintains Target Price $5
    Market Newswire · 2026/9/4
  • Press Release: DNA X, Inc. Reports Second Quarter 2026 Financial Results
    Dow Jones · 2026/8/20
  • Rating change
    TD Cowen Maintains Ginkgo Bioworks(DNA.US) With Buy Rating, Cuts Target Price to $14
    Market Newswire · 2025/11/7
  • Rating change
    BTIG Maintains Ginkgo Bioworks(DNA.US) With Sell Rating, Raises Target Price to $9
    Market Newswire · 2025/8/25
  • Rating change
    William Blair Initiates Ginkgo Bioworks(DNA.US) With Sell Rating
    Market Newswire · 2026/8/6
  • Rating change
    TD Cowen Maintains Ginkgo Bioworks(DNA.US) With Buy Rating, Raises Target Price to $18
    Market Newswire · 2025/10/14
  • Company notice
    8-K: Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward
    SEC · 2025/6/18
  • Kala Bio and Virotek Sign Letter of Intent With U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products
    GlobeNewswire · 2026/9/24
  • Ginkgo Bioworks (DNA.US) will release its earnings report after market close on August 5.
    Market Newswire · 2026/7/31
  • Rating change
    TR | OpenAI - 4o Maintains Ginkgo Bioworks(DNA.US) With Hold Rating, Raises Target Price to $12
    Market Newswire · 2025/8/12
  • Rating change
    Analysts Conflicted on These Healthcare Names: Ginkgo Bioworks Holdings (DNA), Xencor (XNCR) and Alto Neuroscience, Inc. (ANRO)
    TipRanks · 2026/5/11

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 09:20:28 · For reference only, not investment advice and not tailored to your situation.